Myrexis, Inc. (Formerly Known as Myriad Pharmaceuticals, Inc.) Initiates Comparative-Arm Phase 2 Study of Azixa(TM) for the Front-Line Treatment of Glioblastoma Multiforme

SALT LAKE CITY, Dec. 22, 2010 (GLOBE NEWSWIRE) -- Myrexis, Inc. (Nasdaq:MYRX), a biotechnology company focused on discovering, developing, and commercializing novel treatments for cancer, today announced it has initiated a controlled two-arm Phase 2b clinical study of Azixa (verubulin) as a front-line treatment for glioblastoma multiforme (GBM).